David Shibata
A5025906534- Colorectal Cancer Screening and Detection
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Nutrition and Health in Aging
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Esophageal Cancer Research and Treatment
- Cancer survivorship and care
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- RNA modifications and cancer
- Economic and Financial Impacts of Cancer
- Cervical Cancer and HPV Research
- Caveolin-1 and cellular processes
- Global Cancer Incidence and Screening
- Gut microbiota and health
- Radiomics and Machine Learning in Medical Imaging
- Diet and metabolism studies
- Molecular Biology Techniques and Applications
- Intraperitoneal and Appendiceal Malignancies
University of Tennessee Health Science Center
2016-2025
Moffitt Cancer Center
2013-2024
University of Tennessee at Knoxville
2019-2024
St. Jude Children's Research Hospital
2009-2024
Washington University in St. Louis
2024
Center for Cancer Research
2022-2023
Henry Ford Hospital
2022
California Pacific Medical Center
2022
Stony Brook University
2022
State University of New York
2022
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These include recommendations first-line use checkpoint inhibitors mCRC, that is deficient mismatch repair/microsatellite instability-high, related biosimilars, and expanded biomarker testing. The now targeted patients with mCRC...
This portion of the NCCN Guidelines for Colon Cancer focuses on use systemic therapy in metastatic disease. Considerations treatment selection among 32 different monotherapies and combination regimens up to 7 lines have included history, extent disease, goals treatment, efficacy toxicity profiles regimens, KRAS/NRAS mutational status, patient comorbidities preferences. Location primary tumor, BRAF mutation tumor microsatellite stability should also be considered decisions.
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, survivorship. These Insights summarize the Panel discussions 2018 update guidelines risk stratification adjuvant treatment patients with stage III colon cancer,
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer address diagnosis, staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, disease surveillance, survivorship patients with rectal cancer. This portion the guidelines focuses on localized which involves careful patient selection curative-intent treatment options that sequence multimodality therapy usually comprised chemotherapy, radiation, resection.
OverviewColorectal cancer is the fourth most frequently diagnosed and second leading cause of death in United States.In 2009, an estimated 106,100 new cases colon 40,870 rectal will occur.During same year, it that 49,920 people die from cancer. 1 Despite these statistics, mortality has decreased slightly over past 30 years, possibly due to earlier diagnosis through screening better treatment modalities.
This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent include redrawing algorithms stage II III disease reflect new data supporting increasingly prominent role total neoadjuvant therapy, expanded recommendations short-course radiation therapy techniques, a "watch-and-wait" nonoperative technique patients with that shows complete...
In 2009 an estimated 40,870 new cases of rectal cancer will occur in the United States (23,580 men; 17,290 women).During same year, 49,920 people die from and colon cancers. 1 Although colorectal is ranked as fourth most frequently diagnosed second leading cause death States, mortality has decreased during past 30 years.This decrease may be due to earlier diagnosis through screening better treatment modalities.The recommendations these clinical practice guidelines are classified category 2A...
The NCCN Guidelines for Rectal Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These Insights summarize panel discussion behind recent important updates to guidelines. include clarifying definition rectum differentiating from sigmoid colon; total neoadjuvant therapy approach localized cancer; biomarker-targeted metastatic colorectal cancer, a focus on new treatment options BRAF V600E- or HER2 amplification-positive disease.
Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than other related malignancies, including colorectal cancer. Due to rarity this disease, few studies have been done direct optimal treatment, although data shown responds treatment differently cancer, necessitating separate approach treatment. The NCCN Guidelines Bowel...
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion the guidelines focuses on use systemic therapy in disease. colorectal cancer involves a continuum care which patients are exposed sequentially to variety active agents, either combinations or as single agents. Choice is based goals type timing prior therapy, different...
The NCCN Guidelines for Rectal Cancer begin with the clinical presentation of patient to primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management recurrent metastatic disease, survivorship. Panel meets at least annually review comments from reviewers within their institutions, examine relevant new data publications abstracts, reevaluate update recommendations. These Insights...
Identifying individuals with hereditary syndromes allows for timely cancer surveillance, opportunities risk reduction, and syndrome-specific management. Establishing criteria assessment the identification of who are carriers pathogenic genetic variants. The NCCN Guidelines Genetic/Familial High-Risk Assessment: Colorectal provides recommendations management patients at or diagnosed high-risk colorectal syndromes. panel meets annually to evaluate update their based on clinical expertise new...
Colorectal cancer (CRC) is the fourth most frequently diagnosed and second leading cause of death in United States. Management disseminated metastatic CRC involves various active drugs, either combination or as single agents. The choice therapy based on consideration goals therapy, type timing prior mutational profile tumor, differing toxicity profiles constituent drugs. This manuscript summarizes data supporting systemic options recommended for NCCN Guidelines Colon Cancer.
This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents most common histologic form of disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical radiation and radiology is necessary. Primary treatment perianal cancer canal are similar include chemoradiation in cases. Follow-up clinical evaluations recommended all patients with carcinoma because additional curative-intent...
The determination of an optimal treatment plan for individual patient with rectal cancer is a complex process. In addition to decisions relating the intent surgery (ie, curative or palliative), consideration must also be given likely functional results treatment, including probability maintaining restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly patients distal cancer, finding balance between curative-intent therapy while having minimal...
Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic has not been elucidated, DCC (deleted cancer) is candidate. We investigated whether expression protein tumor cells prognostic marker carcinoma.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer begin with the clinical presentation of patient to primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management recurrent metastatic disease, survivorship. Panel meets annually review comments from reviewers within their institutions reevaluate update recommendations. In addition, panel has interim conferences...
These NCCN Clinical Practice Guidelines in Oncology provide recommendations for the management of rectal cancer, beginning with clinical presentation patient to primary care physician or gastroenterologist through diagnosis, pathologic staging, neoadjuvant treatment, surgical management, adjuvant surveillance, recurrent and metastatic disease, survivorship. This discussion focuses on localized disease. The Rectal Cancer Panel believes that a multidisciplinary approach, including...
The NCCN Guidelines for Anal Carcinoma provide recommendations the management of patients with squamous cell carcinoma anal canal or perianal region. Primary treatment cancer usually includes chemoradiation, although certain lesions can be treated margin-negative local excision alone. Disease surveillance is recommended all because additional curative-intent possible. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical radiation and radiology...